CN116359272B - 一种代谢标志物及其在诊断、预测食管癌中的应用 - Google Patents
一种代谢标志物及其在诊断、预测食管癌中的应用 Download PDFInfo
- Publication number
- CN116359272B CN116359272B CN202310346073.5A CN202310346073A CN116359272B CN 116359272 B CN116359272 B CN 116359272B CN 202310346073 A CN202310346073 A CN 202310346073A CN 116359272 B CN116359272 B CN 116359272B
- Authority
- CN
- China
- Prior art keywords
- metabolic
- metabolic marker
- mass spectrometry
- esophageal cancer
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002503 metabolic effect Effects 0.000 title claims abstract description 59
- 239000003550 marker Substances 0.000 title claims abstract description 51
- 206010030155 Oesophageal carcinoma Diseases 0.000 title claims abstract description 43
- 208000000461 Esophageal Neoplasms Diseases 0.000 title claims abstract description 42
- 201000004101 esophageal cancer Diseases 0.000 title claims abstract description 42
- 238000003745 diagnosis Methods 0.000 title claims abstract description 22
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 30
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 28
- WWNNZCOKKKDOPX-UHFFFAOYSA-N N-methylnicotinate Chemical compound C[N+]1=CC=CC(C([O-])=O)=C1 WWNNZCOKKKDOPX-UHFFFAOYSA-N 0.000 claims abstract description 28
- 235000019192 riboflavin Nutrition 0.000 claims abstract description 16
- 239000002151 riboflavin Substances 0.000 claims abstract description 16
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 15
- ZYVXHFWBYUDDBM-UHFFFAOYSA-N N-methylnicotinamide Chemical compound CNC(=O)C1=CC=CN=C1 ZYVXHFWBYUDDBM-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229960002477 riboflavin Drugs 0.000 claims abstract description 15
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 claims abstract description 14
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims abstract description 14
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims abstract description 14
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 claims abstract description 14
- 229940072107 ascorbate Drugs 0.000 claims abstract description 14
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 14
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 14
- 229930010555 Inosine Natural products 0.000 claims abstract description 13
- 229960003786 inosine Drugs 0.000 claims abstract description 13
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 210000002700 urine Anatomy 0.000 claims description 29
- 238000001514 detection method Methods 0.000 claims description 16
- 238000005481 NMR spectroscopy Methods 0.000 claims description 12
- QHKABHOOEWYVLI-UHFFFAOYSA-N 3-methyl-2-oxobutanoic acid Chemical compound CC(C)C(=O)C(O)=O QHKABHOOEWYVLI-UHFFFAOYSA-N 0.000 claims description 9
- 238000004458 analytical method Methods 0.000 claims description 9
- 238000004949 mass spectrometry Methods 0.000 claims description 9
- 238000004611 spectroscopical analysis Methods 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims description 4
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 claims description 4
- 238000004252 FT/ICR mass spectrometry Methods 0.000 claims description 3
- 238000004497 NIR spectroscopy Methods 0.000 claims description 2
- 238000000149 argon plasma sintering Methods 0.000 claims description 2
- 238000000840 electrochemical analysis Methods 0.000 claims description 2
- 238000001962 electrophoresis Methods 0.000 claims description 2
- 238000001437 electrospray ionisation time-of-flight quadrupole detection Methods 0.000 claims description 2
- 238000012921 fluorescence analysis Methods 0.000 claims description 2
- 238000005558 fluorometry Methods 0.000 claims description 2
- 238000004817 gas chromatography Methods 0.000 claims description 2
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 2
- 238000000534 ion trap mass spectrometry Methods 0.000 claims description 2
- 238000004848 nephelometry Methods 0.000 claims description 2
- 238000005173 quadrupole mass spectroscopy Methods 0.000 claims description 2
- 238000005514 radiochemical analysis Methods 0.000 claims description 2
- 238000004885 tandem mass spectrometry Methods 0.000 claims description 2
- 238000004809 thin layer chromatography Methods 0.000 claims description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 claims description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 claims 2
- 238000001269 time-of-flight mass spectrometry Methods 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 7
- 206010041823 squamous cell carcinoma Diseases 0.000 description 30
- 239000002207 metabolite Substances 0.000 description 27
- 210000001519 tissue Anatomy 0.000 description 26
- 230000004060 metabolic process Effects 0.000 description 20
- 239000000523 sample Substances 0.000 description 15
- 210000001124 body fluid Anatomy 0.000 description 12
- 239000010839 body fluid Substances 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 10
- 230000037353 metabolic pathway Effects 0.000 description 10
- 239000000090 biomarker Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 5
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 5
- 230000002980 postoperative effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000003238 esophagus Anatomy 0.000 description 4
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- OIIWPAYIXDCDNL-UHFFFAOYSA-M sodium 3-(trimethylsilyl)propionate Chemical compound [Na+].C[Si](C)(C)CCC([O-])=O OIIWPAYIXDCDNL-UHFFFAOYSA-M 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000000738 capillary electrophoresis-mass spectrometry Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002790 cross-validation Methods 0.000 description 3
- 238000013399 early diagnosis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000132 electrospray ionisation Methods 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000003068 pathway analysis Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 208000028653 esophageal adenocarcinoma Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- VVIUBCNYACGLLV-UHFFFAOYSA-N hypotaurine Chemical compound [NH3+]CCS([O-])=O VVIUBCNYACGLLV-UHFFFAOYSA-N 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 230000008463 key metabolic pathway Effects 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000010239 partial least squares discriminant analysis Methods 0.000 description 2
- 238000012567 pattern recognition method Methods 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000007637 random forest analysis Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 108010088201 squamous cell carcinoma-related antigen Proteins 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000012706 support-vector machine Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101100043112 Homo sapiens SERPINB3 gene Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010066302 Keratin-19 Proteins 0.000 description 1
- 102000018317 Keratin-19 Human genes 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100036383 Serpin B3 Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 108010036226 antigen CYFRA21.1 Proteins 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000009614 chemical analysis method Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000023266 generation of precursor metabolites and energy Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 238000002705 metabolomic analysis Methods 0.000 description 1
- 230000001431 metabolomic effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 238000001558 permutation test Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 238000000079 presaturation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 150000003287 riboflavins Chemical class 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000264 spin echo pulse sequence Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
- G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- High Energy & Nuclear Physics (AREA)
- Hematology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310346073.5A CN116359272B (zh) | 2023-04-03 | 2023-04-03 | 一种代谢标志物及其在诊断、预测食管癌中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310346073.5A CN116359272B (zh) | 2023-04-03 | 2023-04-03 | 一种代谢标志物及其在诊断、预测食管癌中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116359272A CN116359272A (zh) | 2023-06-30 |
CN116359272B true CN116359272B (zh) | 2023-11-10 |
Family
ID=86931717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310346073.5A Active CN116359272B (zh) | 2023-04-03 | 2023-04-03 | 一种代谢标志物及其在诊断、预测食管癌中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116359272B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105044361A (zh) * | 2015-08-14 | 2015-11-11 | 山东省肿瘤防治研究院 | 一种适合于食管鳞状细胞癌早期诊断的诊断标记物及其筛选方法 |
CN105572355A (zh) * | 2015-03-13 | 2016-05-11 | 中国医学科学院肿瘤医院 | 检测食管癌的生物标志物 |
WO2017155467A1 (en) * | 2016-03-08 | 2017-09-14 | Agency For Science, Technology And Research | Methods of diagnosing cancer |
CN113533560A (zh) * | 2021-06-30 | 2021-10-22 | 郑州大学第一附属医院 | 基于代谢组学的食管癌早期筛查标志物及其试剂盒 |
CN115684451A (zh) * | 2022-09-13 | 2023-02-03 | 北京大学人民医院 | 基于代谢组学的食管鳞癌淋巴结转移诊断标志物及其应用 |
-
2023
- 2023-04-03 CN CN202310346073.5A patent/CN116359272B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105572355A (zh) * | 2015-03-13 | 2016-05-11 | 中国医学科学院肿瘤医院 | 检测食管癌的生物标志物 |
CN105044361A (zh) * | 2015-08-14 | 2015-11-11 | 山东省肿瘤防治研究院 | 一种适合于食管鳞状细胞癌早期诊断的诊断标记物及其筛选方法 |
WO2017155467A1 (en) * | 2016-03-08 | 2017-09-14 | Agency For Science, Technology And Research | Methods of diagnosing cancer |
CN113533560A (zh) * | 2021-06-30 | 2021-10-22 | 郑州大学第一附属医院 | 基于代谢组学的食管癌早期筛查标志物及其试剂盒 |
CN115684451A (zh) * | 2022-09-13 | 2023-02-03 | 北京大学人民医院 | 基于代谢组学的食管鳞癌淋巴结转移诊断标志物及其应用 |
Non-Patent Citations (2)
Title |
---|
~1H-MRS定量测定脑代谢物的研究;林艳, 饶海冰, 吴仁华;国外医学.放射医学核医学分册(第02期);85-88 * |
1H NMR-based metabolomics of paired tissue, serum and urine samples reveals an optimized panel of biofluids metabolic biomarkers for esophageal cancer;Changchun Ma et al.;Front. Oncol.;第13卷;1-13 * |
Also Published As
Publication number | Publication date |
---|---|
CN116359272A (zh) | 2023-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dinges et al. | Cancer metabolomic markers in urine: evidence, techniques and recommendations | |
Park et al. | Metabolomic-derived novel cyst fluid biomarkers for pancreatic cysts: glucose and kynurenine | |
Issaq et al. | Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry | |
JP6692422B2 (ja) | 尿中代謝物による疾病診断法 | |
US20150087553A1 (en) | Early trimester screening for early- and late-onset preeclampsia | |
RU2666255C2 (ru) | Метилглиоксаль в качестве маркера злокачественной опухоли | |
JP7288283B2 (ja) | 小児がん検査用尿中代謝物マーカー | |
WO2017003936A1 (en) | Methods for detecting, diagnosing and treating endometrial cancer | |
Siddiqui et al. | Metabolomics: an emerging potential approach to decipher critical illnesses | |
Roberts et al. | Seminal plasma enables selection and monitoring of active surveillance candidates using nuclear magnetic resonance-based metabolomics: A preliminary investigation | |
Skorupa et al. | Grading of endometrial cancer using 1H HR-MAS NMR-based metabolomics | |
WO2013154998A1 (en) | Serum biomarkers and pulmonary nodule size for the early detection of lung cancer | |
US8133736B2 (en) | Methods for detecting or monitoring cancer using LPE as a marker | |
Kozar et al. | Identification of novel diagnostic biomarkers in endometrial cancer using targeted metabolomic profiling | |
Issaq et al. | Biomarker discovery: study design and execution | |
JP6421118B2 (ja) | 前立腺摘出術後の前立腺癌の再発の診断のための手段および方法 | |
CN116359272B (zh) | 一种代谢标志物及其在诊断、预测食管癌中的应用 | |
JP7226732B2 (ja) | 尿中腫瘍マーカーによるがん検出方法、キット及び装置 | |
EP3622295A1 (en) | Cholesteryl linoleate (18:2) in feces samples as biomarker for colorectal cancer | |
CN116465920B (zh) | 用于诊断食管癌的代谢标志物 | |
EP2836833A1 (en) | Prenatal screening for down syndrome and trisomy 18 | |
US9885719B2 (en) | Composition comprising lysophosphatidylcholine and homocysteic acid for ovarian cancer diagnosis and method using the same | |
CN116430049B (zh) | 食管癌的代谢标志物及其应用 | |
CN118091155A (zh) | 大肠癌代谢标志物及其在诊断大肠癌中的应用 | |
Sharma et al. | MR spectroscopy in breast cancer metabolomics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240407 Address after: No.69 Dongxia North Road, Guangxia New City, Shantou City, Guangdong Province, 515041 Patentee after: THE SECOND AFFILIATED HOSPITAL OF SHANTOU UNIVERSITY MEDICAL College Country or region after: China Patentee after: CANCER HOSPITAL OF SHANTOU UNIVERSITY MEDICAL College Address before: 515041 No. 22 Ling Road, Guangdong, Shantou Patentee before: SHANTOU UNIVERSITY MEDICAL College Country or region before: China |